The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009The Role of Casein Kinase 2 in the Modulation of Dopamine Signaling in Parkinson's Disease
Objective/Rationale:
Parkinson’s disease is caused by a selective loss of cells in the brain that produce the neurotransmitter dopamine. The major treatment for PD is Levodopa (L-Dopa) which gets... -
Research Grant, 2022Development And Validation Of A Miro1 Biomarker Assay Using White Blood Cells
Study Rationale: The mitochondrial protein Miro1 fails to be degraded and this defect impairs mitophagy in more than 90% of all Parkinson’s disease (PD) patients of both genetic and sporadic forms...
-
Aligning Science Across Parkinson's, 2021Understanding and Manipulating Cellular and Circuit-level Vulnerability to Neurodegeneration in Parkinson’s Disease
Study Rationale:
Many people with Parkinson’s disease develop untreatable cognitive symptoms, including problems with attention, decision-making, and dementia at late stages of the disease, due to... -
Therapeutic Pipeline Program, 2013Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease
Objective/Rationale:
Erythropoietin (EPO) receptor is present throughout the body and plays a role in both red blood cell production and tissue protection. STATegics has discovered small... -
Therapeutic Pipeline Program, 2013Exenatide as a Treatment for Patients with Parkinson’s Disease
Objective/Rationale:
Laboratory data from several teams have indicated potential beneficial effects of the drug Exenatide on the survival of dopamine cells. In a small group of patients... -
Dyskinesia Challenge, 2012The Effects of Memantine on Levodopa Induced Dyskinesias (LIDs) in MPTP-treated Pre-clinical Models
Objective/Rationale:
Levodopa is the mainstay of treatment for the motor symptoms of Parkinson’s disease. Unfortunately one of the long term side effects of levodopa treatment is the development of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.